Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.

Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — ...

U.S. President-elect Donald Trump will not go to jail or face any other punishment for his criminal conviction stemming from hush money paid to a porn star, a judge ruled on Friday but said Trump ...

Whether you’re a fan of the All Blacks, a follower of the women’s game or someone who watches every phase of play in the Premiership, our rugby features and news pieces will provide you with all of ...